EMERGENT BIOSOLUTIONS INC. (EBS) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | Gross Profit |
| Revenue | 770.20M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 339.90M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $770.20M | $339.90M | (m) |
| 2026-03-31 | (m) | $676.80M | $309.70M | (m) |
| 2025-12-31 | (m) | $742.90M | $326.20M | (m) |
| 2025-09-30 | (m) | $788.90M | (m) | (m) |
| 2025-06-30 | (m) | $851.60M | (m) | (m) |
| 2025-03-31 | (m) | $965.40M | (m) | (m) |
| 2024-12-31 | (m) | $1.04B | (m) | (m) |
| 2024-09-30 | $345.80M | $1.13B | $748.40M | 30.72% |
| 2024-06-30 | $271.80M | $1.10B | $802.60M | 24.66% |
| 2024-03-31 | $460.50M | $1.19B | $697.10M | 38.85% |
| 2023-12-31 | $317.60M | $1.05B | $705.40M | 30.27% |
| 2023-09-30 | $335.40M | $1.10B | $740.80M | 30.41% |
| 2023-06-30 | $322.40M | $1.07B | $713.70M | 30.03% |
| 2023-03-31 | $247.30M | $978.50M | $692.90M | 25.27% |
| 2022-12-31 | $385.80M | $1.12B | $693.70M | 34.42% |
| 2022-09-30 | (m) | $1.51B | (m) | (m) |
| 2022-06-30 | (m) | $1.60B | (m) | (m) |
| 2022-03-31 | (m) | $1.76B | (m) | (m) |
| 2021-12-31 | (m) | $1.79B | (m) | (m) |
| 2021-09-30 | (m) | $1.65B | (m) | (m) |
| 2021-06-30 | (m) | $1.71B | $644.40M | (m) |
| 2021-03-31 | (m) | $1.71B | $546.40M | (m) |
| 2020-12-31 | (m) | $1.56B | $524.00M | (m) |
| 2020-09-30 | (m) | $1.33B | $488.50M | (m) |
| 2020-06-30 | (m) | $1.26B | $447.50M | (m) |
| 2020-03-31 | (m) | $1.11B | $418.60M | (m) |
| 2019-12-31 | $114.10M | $1.11B | $433.50M | 10.32% |
| 2019-09-30 | (m) | $351.80M | $414.20M | (m) |
| 2019-06-30 | (m) | $213.70M | $375.60M | (m) |
| 2019-03-31 | (m) | $190.60M | $359.80M | (m) |
| 2018-12-31 | $89.80M | $782.40M | $322.30M | 11.48% |
| 2018-09-30 | (m) | $705.48M | (m) | (m) |
| 2018-06-30 | (m) | $681.26M | (m) | (m) |
| 2018-03-31 | (m) | $561.83M | (m) | (m) |
| 2017-12-31 | $124.28M | $560.87M | (m) | 22.16% |
| 2017-09-30 | (m) | $518.73M | (m) | (m) |
| 2017-06-30 | (m) | $512.21M | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) |
| 2016-12-31 | $105.52M | $488.78M | (m) | 21.59% |
| 2016-09-30 | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $545.53M | (m) | (m) |
| 2016-03-31 | (m) | $570.16M | (m) | (m) |
| 2015-12-31 | (m) | $522.79M | (m) | (m) |
| 2015-09-30 | (m) | $502.66M | (m) | (m) |
| 2015-06-30 | (m) | $475.67M | (m) | (m) |
| 2015-03-31 | (m) | $459.89M | (m) | (m) |
| 2014-12-31 | (m) | $450.14M | (m) | (m) |
| 2014-09-30 | (m) | $400.27M | (m) | (m) |
| 2014-06-30 | (m) | $351.42M | (m) | (m) |
| 2014-03-31 | (m) | $323.53M | (m) | (m) |
| 2013-12-31 | (m) | $312.75M | (m) | (m) |
| 2013-09-30 | (m) | $309.24M | (m) | (m) |
| 2013-06-30 | (m) | $286.73M | (m) | (m) |
| 2013-03-31 | (m) | $274.68M | (m) | (m) |
| 2012-12-31 | (m) | $281.89M | (m) | (m) |
| 2012-09-30 | (m) | $295.23M | (m) | (m) |
| 2012-06-30 | (m) | $287.40M | (m) | (m) |
| 2012-03-31 | (m) | $305.16M | (m) | (m) |
| 2011-12-31 | (m) | $273.38M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $286.17M | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $234.79M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |